Schuck S, Allain H, Gandon J M, Patat A, Millet V, Le Coz F
Laboratoire de Pharmacologie Clinique, Faculté de médecine, Université Rennes I, France.
Fundam Clin Pharmacol. 1998;12(4):463-7. doi: 10.1111/j.1472-8206.1998.tb00973.x.
The effect of 3 dosages of bromazepam administered as single oral doses (1.5, 3 and 6 mg) on anxious inhibition phenomena was studied in a population of 16 young women (18-30 years) with anxiety-traits, selected on the criteria of Cattell's anxiety scale supported by two personality inventory (Eysenck's, MMPI). A double-blind, placebo study design was chosen. The main assessment criteria were based on the go/no-go test (Logan's procedure), slow response rate (SRR) and a task of forced or unforced decision (use of the CFF). Attentional processes and declarative memory were analyzed as secondary criteria. None of the three dosages modified inhibition or acting-out. Sustained attention was reduced with 1.5 mg and 6 mg, as was memory performance with 3 and 6 mg, 3.5 h after drug administration. In contradistinction with studies carried out in healthy volunteers or with other benzodiazepine compounds, bromazepam at single low dosages does not modify inhibition capacity in these subjects with traits of anxiety, in this particular procedure.
在16名年龄在18至30岁之间、具有焦虑特质的年轻女性群体中，研究了单次口服三种剂量（1.5毫克、3毫克和6毫克）溴西泮对焦虑抑制现象的影响。这些女性是根据卡特尔焦虑量表标准并辅以两种人格量表（艾森克量表、明尼苏达多项人格调查表）挑选出来的。采用双盲、安慰剂研究设计。主要评估标准基于停止信号测试（洛根程序）、慢反应率（SRR）以及强制或非强制决策任务（使用临界闪光融合频率）。注意力过程和陈述性记忆作为次要标准进行分析。三种剂量均未改变抑制或冲动行为。给药3.5小时后，1.5毫克和6毫克剂量降低了持续注意力，3毫克和6毫克剂量降低了记忆表现。与在健康志愿者或使用其他苯二氮䓬类化合物所进行的研究不同，在此特定程序中，单次低剂量溴西泮不会改变这些具有焦虑特质受试者的抑制能力。
